CS MEDICA is pleased to announce a progression in its collaboration within Jordan, following the confirmed classification of its core portfolio as medical devices with cannabidiol (CBD). This development aligns with Jordan's recent regulatory framework that allows products with low THC concentrations in the market. This is a progressive step for the region, especially within the Middle Eastern and North African (MENA) territories known for their stringent regulatory environments. This decision is anticipated to catalyze further regulatory advancements across the growing MENA region, particularly in territories keen on integrating evidence-based, alternative medicines with minimal side effects into their healthcare systems.

With products now classified as medical devices with CBD, CS MEDICA is set to begin the detailed process of individual product registrations. This classification underscores the safety and compliance of its offerings, facilitating the registration process with greater precision and assurance.
 

Our portfolio's classification as medical devices with CBD positions us to confidently approach the final stages of product registration in Jordan," stated Lone Henriksen, CEO of CS MEDICA. "This milestone potentially indicates the upcoming launch of CANNASEN®, backed by a preliminary distribution agreement for 100,000 units through Nabih Nabulsi Drugstores, but may also accelerate the registration processes across other countries in the MENA region. We believe that establishing this precedent in Jordan could streamline our efforts with several strategic partners throughout MENA, potentially leading to fulfilling a large part of our order pipeline."

Compliance with local and international regulations is paramount in the alternative treatment landscape, especially in industries like CBD, where safety, high quality, and proof of concept are critical. CS MEDICA adheres strictly to these regulations to ensure that its products meet and exceed the strict standards set forth for medical devices.

The MENA region exhibits a burgeoning market for products containing CBD, expected to reach a market size of USD 156.3 million by 2024, with a compound annual growth rate (CAGR) of 15.9% (Cognitive Market Research (https://www.cognitivemarketresearch.com/regional-analysis/middle-east-and-africa-cbd-product-market-report)). The region's increasing health consciousness and economic growth enhance consumer demand for high-quality, pharmaceutical-grade CBD-infused products (Cognitive Market Research (https://www.cognitivemarketresearch.com/regional-analysis/middle-east-and-africa-cbd-beverages-market-report)).

Lone continues: "This milestone is part of our ongoing efforts to enhance healthcare with innovative treatments that meet stringent safety standards. As we move forward, our focus remains on providing products that adhere to local regulatory requirements and offer new therapeutic options for patients seeking effective alternatives to conventional treatments."